Jobevne (bevacizumab-nwgd)

Adult Dosing .

Dosage forms:  INJ

New FDA Approval: April 2025

[content coming soon]

colorectal CA, metastatic

[content coming soon]

nonsquamous non-small cell lung CA, first-line tx

[content coming soon]

glioblastoma, recurrent

[content coming soon]

renal cell CA, metastatic

[content coming soon]

cervical CA, persistent or recurrent or metastatic

[content coming soon]

ovarian CA

[content coming soon]

Peds Dosing .

Dosage forms:  --

New FDA Approval: April 2025

[Peds dosing is not applicable for this drug]